A


Percent survival
100
50
0
0
100
200
300
400
Days
ADC n = 78
SqCC n = 42
NSCLC-NOS n = 27
***
**

B


Percent survival
100
50
0
0
100
200
300
400
Days
ADC n = 78
ADC EbUS n = 9
**

C


Percent survival
100
50
0
0
100
200
300
400
Days
SqCC n = 42
SqCC EbUS n = 6

D


ADC
SqCC
t0
t1
t0
t1
surgery
EbUS
n/a

Weeden *et al* Supp Figure 2



A


792
788
926
t0
t1
t4
B allele freq
0.0
0.4
0.8
0.0e+00
5.0e+07
position on chromosome 8
2
1
0
-1
-2

B


792
406
788
926
CCND1
CEP11

C


FGFR1 expression (relative to 18S)
0.01
0.001
0.0001
0.00001
0.000001
926
788
792
406

D


FGFR1 RNA expression
4
6
8
10
−1
0
1
2
3
FGFR1 copy number

A


Overall survival by FGFR1 mRNA expression
Cumulative survival
0.00
0.25
0.50
0.75
1.00
None
High
0
60
120
Time (months)

B


Disease-free survival by FGFR1 mRNA expression
Cumulative survival
0.00
0.25
0.50
0.75
1.00
None
High
0
60
120
Time (months)

A


788: FGFR1amp,+++
926: FGFR1+++
54 kDa -
PTEN
45 kDa -
actin

B


788: FGFR1amp,+++
926: FGFR1+++
t0
t1
t4
B Allele Freq
0.0
0.4
0.8
1.0e+08
1.5e+08
2.0e+08
position on chromosome 3
2
1
0
-1
-2

C


788: FGFR1amp,+++
926: FGFR1+++
Up relative to normal lung
Down relative to normal lung
In LOH region
Protein altering mutation
COSMIC mutation
Gene copy number from SNP array
Gene expression relative to normal lung
PIK3CA
PIK3C2B
PIK3CB
PIK3C2A
PIK3C2G
PIK3CD

A


H1581: FGFR1amp, +++
cell viability %
(relative to control)
100
50
0
***
***
***
-
+
-
+
BGJ-398
DMSO
cisplatin

B


406: FGFR1amp
cell viability %
(relative to control)
100
50
0
***
-
+
-
+
BGJ-398
DMSO
cisplatin

C


406: FGFR1amp
Tumour volume (mm3)
800
600
400
200
0
0
5
10
15
20
25
Time since treatment start (days)
Percentage survival
100
50
0
Time since treatment start (days)
Vehicle
BGJ398
cisplatin
BGJ398+cisplatin
**
**
***